文献速递银屑病与炎症性皮肤病

维生素D补充对血清25-羟维生素D水平较低银屑病患者严重程度的影响:一项随机临床试验

Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2023-01-01

这项随机双盲安慰剂对照试验在挪威特罗姆瑟纳入122例活动性斑块状银屑病且25-羟维生素D低于24 ng/mL的成人,比较口服维生素D(负荷剂量100000 IU后每周20000 IU)与安慰剂4个月的效果。结果显示两组PASI评分变化无显著差异(校正差值0.11,95%CI -0.23至0.45),其他次要结局亦无显著差异,未登记不良事件。

要点

  • 维生素D补充未影响银屑病严重程度,PASI变化组间无显著差异。
  • 基线严重程度评分较低可能解释了未观察到可测量效果。
  • 干预组25(OH)D升高幅度低于基于既往数据的预期,可能影响结果。

核心结论

  • 本随机临床试验结果未观察到维生素D补充对银屑病严重程度有影响。
  • 基线严重程度评分较低可能解释了未观察到可测量效果。
  • 干预组25(OH)D水平升高幅度低于基于同一来源人群既往实验数据的预期,这可能影响了结果。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,2个平行组,在2017至2018年和2018至2019年两个冬季进行。
  • randomization由计算机生成,所有参与者、临床医生和结局评估者对分组设盲。
  • 每个参与者随访4个月;分析于2022年5月进行。
  • 试验在挪威北挪威大学医院(特罗姆瑟;挪威)临床研究单元开展。
  • 纳入特罗姆瑟一般人群中患有活动性斑块状银屑病且25-羟维生素D水平低于24 ng/mL(换算为nmol/L需乘以2.496)的成人。

主要发现

  • 完成时,平均(SD)25(OH)D水平为维生素D组29.7(5.2)ng/mL,安慰剂组12.0(3.8)ng/mL。
  • PASI评分变化组间无显著差异(校正差值0.11;95%CI -0.23至0.45)。
  • 医师总体评估评分变化组间无显著差异(校正比值比0.66;95%CI 0.27-1.63)。
  • 自评PASI变化组间无显著差异(校正差值-0.60;95%CI -1.76至0.55)。
  • 皮肤病生活质量指数变化组间无显著差异(校正差值-0.86;95%CI -1.9至0.19)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 基线严重程度评分较低可能解释了未观察到可测量效果。
  • 干预组25(OH)D水平升高幅度低于基于同一来源人群既往实验数据的预期,这可能影响了结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Topical vitamin D analogues are routine treatment for psoriasis, but the effect of oral supplementation has not been established. OBJECTIVE: To examine the effect of vitamin D supplementation on psoriasis severity throughout the winter. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind placebo-controlled clinical trial with 2 parallel groups was performed through 2 winter seasons (2017 to 2018 and 2018 to 2019). Randomization was computer generated. All participants, health care clinicians, and outcome assessors were masked to group assignment. Each participant was followed for 4 months. The presented analyses were conducted in May 2022. The trial was conducted at the clinical research unit of the University Hospital of North Norway (Tromsø; Norway). Adults from the general population in Tromsø with active plaque psoriasis and 25-hydroxyvitamin D (25[OH]D) levels of less than 24 ng/mL (to convert to nmol/L, multiply by 2.496) were included. INTERVENTION: Vitamin D (cholecalciferol, 100 000 IU, loading dose, followed by 20 000 IU/week) or placebo for 4 months. MAIN OUTCOMES AND MEASURES: Psoriasis Area Severity Index (PASI) (primary outcome), Physician Global Assessment, self-administered PASI, and Dermatology Life Quality Index scores (secondary outcomes). RESULTS: A total of 122 participants (46 women [37.7%]; mean [SD] age, 53.6 [10.0] years; mean [SD] PASI score, 3.1 [2.0]; mean [SD] serum 25(OH)D, 14.9 [3.9] ng/mL) were included. Of these, 60 (49.2%) were randomized to the vitamin D group and 62 (50.8%) to the placebo group. A total of 120 participants (59 vitamin D [49.2%]/61 placebo [51.8%]) completed the study. By completion, mean (SD) 25(OH)D levels were 29.7 (5.2) ng/mL (vitamin D) and 12.0 (3.8) ng/mL (placebo). There was no significant difference in change in PASI score between the groups (adjusted difference, 0.11; 95% CI, -0.23 to 0.45). There was no significant difference in change in Physician Global Assessment score (adjusted odds ratio, 0.66; 95% CI, 0.27-1.63), self-administered PASI (adjusted difference, -0.60; 95% CI, -1.76 to 0.55) or Dermatology Life Quality Index (adjusted difference, -0.86; 95% CI, -1.9 to 0.19) between the groups. No adverse effects of the intervention were registered. CONCLUSION AND RELEVANCE: The results of this randomized clinical trial showed that vitamin D supplementation did not affect psoriasis severity. Low baseline severity scores may explain the lack of measurable effect. Levels of 25(OH)D in the intervention group increased to a less-than-expected degree based on previous experimental data from the same source population, and this may have affected the results. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03334136.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Jenssen M, Furberg AS, Jorde R, et al. Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial. JAMA Dermatol. 2023. PMID: 36988936. doi:10.1001/jamadermatol.2023.0357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。